A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible Cancers

NCT02643303 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

58

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
Breast Cancer
Sarcoma
Merkel Cell Carcinoma
Cutaneous T-Cell Lymphoma
Melanoma
Renal Cancer
Bladder Cancer
Prostate Cancer
Testicular Cancer
Solid Tumor

Interventions

DRUG: Durvalumab
DRUG: Tremelimumab
DRUG: Poly-ICLC

Sponsor

Ludwig Institute for Cancer Research

Collaborators

[object Object]
[object Object]